INT195060

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.73
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 9
Disease Relevance 4.82
Pain Relevance 1.30

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (ALPL) plasma membrane (ALPL)
Anatomy Link Frequency
leukocytes 1
osteoblasts 1
arm 1
ALPL (Homo sapiens)
Pain Link Frequency Relevance Heat
Infliximab 3 99.10 Very High Very High Very High
spondylitis 6 98.08 Very High Very High Very High
Inflammation 82 89.40 High High
spinal inflammation 75 88.16 High High
headache 5 87.52 High High
cINOD 54 83.72 Quite High
antagonist 16 83.64 Quite High
cytokine 4 73.52 Quite High
withdrawal 4 65.24 Quite High
colic 1 57.36 Quite High
Disease Link Frequency Relevance Heat
Osteoporosis 179 99.68 Very High Very High Very High
Disease Progression 12 99.52 Very High Very High Very High
Phosphate Metabolism Disorders 110 98.64 Very High Very High Very High
Low Back Pain 49 98.08 Very High Very High Very High
Hypophosphatasia 48 97.92 Very High Very High Very High
Ankylosis 2 93.20 High High
Hypercalcemia 42 92.48 High High
INFLAMMATION 122 89.40 High High
Headache 5 87.52 High High
Prostate Cancer 222 86.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Nevertheless, it is important to analyze this particular effect in more detail in the future, because induction of TNSALP gene expression might be a therapeutic target in HP.
Gene_expression (expression) of TNSALP associated with phosphate metabolism disorders
1) Confidence 0.73 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1533806 Disease Relevance 0.15 Pain Relevance 0.28
The dominant effect of TNAP mutations
Gene_expression (mutations) of TNAP
2) Confidence 0.66 Published 2007 Journal Orphanet J Rare Dis Section Body Doc Link PMC2164941 Disease Relevance 0.30 Pain Relevance 0
TNSALP, measured in leukocytes, was at the lowest detectable level in all patients (mean 0.15 nmol/min/mg protein, range 0–0.5 nmol/min/mg protein, normal range 2–18 nmol/min/mg protein) (Table 1).
Gene_expression (detectable) of TNSALP in leukocytes
3) Confidence 0.49 Published 2006 Journal Orphanet J Rare Dis Section Body Doc Link PMC1533806 Disease Relevance 0.09 Pain Relevance 0.11
Recent biomarker data generated from ASSERT (Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy) [22,40] showed that previously low levels of osteocalcin and bone alkaline phosphatase were significantly increased under infliximab therapy [41].
Gene_expression (levels) of bone alkaline phosphatase associated with low back pain, spondylitis and infliximab
4) Confidence 0.12 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2592781 Disease Relevance 0.86 Pain Relevance 0.58
Serum levels of PINP, procollagen type I C-terminal peptide, and bone alkaline phosphatase show significant rises after one month of treatment with teriparatide.
Gene_expression (levels) of bone alkaline phosphatase
5) Confidence 0.11 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2963159 Disease Relevance 0.41 Pain Relevance 0.03
There was improvement in bone alkaline phosphatase (?
Gene_expression (improvement) of bone alkaline phosphatase
6) Confidence 0.06 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895780 Disease Relevance 0.75 Pain Relevance 0.14
In exploratory analyses, however, bone alkaline phosphatase and PSA levels were significantly lower in the atrasentan arm.
Gene_expression (levels) of bone alkaline phosphatase in arm
7) Confidence 0.06 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895780 Disease Relevance 1.17 Pain Relevance 0.16
At 12 months, levels of serum C-telopeptide of type I collagen, bone-specific alkaline phosphatase, and N-terminal propeptide of type I collagen were 59% (95% confidence interval [CI]: 55, 63), 30% (95% CI: 27, 32), and 58% (95% CI: 55, 60) lower, respectively, in the zoledronic acid group (P <0.001 for all) compared with placebo.
Gene_expression (levels) of bone-specific alkaline phosphatase
8) Confidence 0.05 Published 2010 Journal Core evidence Section Body Doc Link PMC2899787 Disease Relevance 0.43 Pain Relevance 0
A recent study has shown that strontium ranelate increases the expression of the bone-specific alkaline phosphatase (bALP; osteoblast differentiation) and the number of the bone nodules (osteoblast activity) of murine osteoblasts.
Gene_expression (expression) of bone-specific alkaline phosphatase in osteoblasts associated with osteoporosis
9) Confidence 0.03 Published 2010 Journal Osteoporos Int Section Body Doc Link PMC2931762 Disease Relevance 0.64 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox